Therapeutics & platforms

Twenty-five subjects, and the same three constraints keep deciding outcomes. Delivery is everything, and the last step of the journey decides. Nucleic-acid drugs pair trivial target selection with a delivery problem so hard that almost all of them are liver drugs; mRNA waited for an immune-silent transcript and a particle that escapes the endosome — barely; an antibody–drug conjugate is decided by its linker; a Gram-negative pathogen has two independent lines of defence; and an in vivo gene-therapy dose almost never gets a second attempt.

The process defines the drug. A protein made by a living cell is defined by how it was made — which is why quality cannot be tested into a batch, why validation argues from the process, and why fill–finish builds sterility by excluding a contaminant that is usually the operator.

Specificity cuts both ways. A phage that replicates at the infection site also hands bacteria an escape route; CAR-T inherits the limits of the surface it sees; TCR therapy opens the inside of the cell and removes the safety filter thymic selection built.

Start with biopharmaceuticals: it establishes process-defined medicine, the frame the platform, cell-therapy and validation pages all work inside.

AI drug design and AlphaFold applications The signal AlphaFold reads out of sequence alignments, what a predicted structure is and is not, and the energy-accuracy barrier that keeps computational design from replacing the assay.
Bacteriophage therapy Receptor recognition, the self-amplifying dose, resistance by receptor loss, and the reasons a self-replicating biological agent does not fit the clinical trial machinery built for fixed doses.
CAR-T cell therapy How a chimeric antigen receptor rewires T-cell activation, why the approved targets are all on expendable tissues, and the trafficking and antigen problems that keep the approach out of solid tumours.
Fill–finish and aseptic biomanufacturing Why terminal sterilisation is unavailable to proteins, how unidirectional airflow and barrier separation substitute for it, and the container-interface chemistry that damages the product after it is filled.
mRNA platforms and LNP delivery Nucleoside modification and innate immune sensing, the ionisable-lipid mechanism of endosomal escape, and the single-digit escape efficiency and liver tropism that bound what the platform can treat.
Process validation and equipment qualification The sampling statistics that make end-product testing insufficient, the evidence structure of the three-stage validation lifecycle, and the scale-down assumption every clearance claim rests on.
Radiopharmaceuticals and theranostics Matched diagnostic and therapeutic pairs, why beta crossfire and alpha track structure kill differently, the organs that set the dose limit, and the decay clock that governs supply.
TCR-engineered T-cell therapy Peptide–MHC recognition and its extreme sensitivity, why HLA restriction fragments the patient population, and the cross-reactivity that killed patients when affinity was engineered upward.
Next-generation antibiotics against AMR The molecular mechanisms of resistance — beta-lactamases across the four Ambler classes, the porin barrier and efflux pumps — and the accumulation rules that cap the chemical space available to new antibiotics.
Biologics The structural logic of antibodies: why the Fc sets half-life, why glycosylation forces mammalian expression, and why aggregation and viscosity cap the whole class.
Biosynthetic steroids Microbial degradation of the phytosterol side chain and regioselective hydroxylation of the steroid nucleus by cytochrome P450: chemistry that synthesis has never reproduced, and the solubility limit that caps output.
Chemoenzymatic API synthesis Selectivity as a property of the binding pocket, the thermodynamics of transamination, and nicotinamide cofactor recycling: what makes a biocatalytic step pay, and what stops it transferring to the next substrate.
In vivo gene therapy: AAV and lentiviral vectors AAV episomal persistence versus lentiviral integration, the 4.7 kb packaging limit and capsid immunology: the three constraints that decide which diseases vector gene therapy can reach.
NK-cell and CAR-NK therapy Missing-self recognition, the balance of activating and inhibitory receptors, and the absence of a clonal TCR: what makes NK cells inherently allogeneic and what limits their persistence.
PROTACs and targeted protein degradation The ternary complex, cooperativity and the ubiquitin-proteasome system: how event-driven degraders work catalytically, why the hook effect exists, and what a molecule of nearly a thousand daltons costs.
ADAR RNA editing therapeutics Hydrolytic adenosine deamination by ADAR, directed by an antisense oligonucleotide: reversible correction without a DNA break, bounded by A-to-I chemistry and by hepatic delivery.
TIL therapy Tumour-infiltrating lymphocytes: neoantigen recognition without genetic engineering, lymphodepletion as the freeing of a cytokine niche, and the structural conflict between dose and differentiation.
Antibody-drug conjugates The targeting, internalisation and linker chemistry behind ADCs, and the reason their dose-limiting toxicities are almost never on-target.
Biopharmaceuticals The shared physical chemistry of protein therapeutics — folding, glycosylation, immunogenicity and FcRn recycling — that every platform in this cluster inherits.
Bispecific antibodies Why forced proximity is the actual mechanism of bispecific antibodies, and how it produces both their potency and their cytokine release syndrome.
Drug and vaccine development The inferential machinery of clinical development — dose-exposure-response, endpoints, randomisation and correlates of protection — and why attrition is a property of biology rather than of process.
Microbiome therapeutics and live biotherapeutics Colonisation resistance as a chemical mechanism, and the engraftment problem that separates a working live biotherapeutic from a hopeful one.
Nucleic acid therapeutics The three silencing mechanisms of therapeutic oligonucleotides, the chemistry that keeps them alive in vivo, and the endosomal escape bottleneck that sets the dose.
Psychedelic medicine and neuroplastic agents 5-HT2A signalling, dendritic spine growth and the intracellular-receptor hypothesis behind psychoplastogens, and why functional unblinding is the field's binding constraint.
Stem cell therapy in autoimmune disease Why MSC immunomodulation depends on the recipient's inflammation rather than on engraftment, how regulatory T cells differ, and why potency assays are the field's unsolved problem.